Riskpilot← Back to searchSign inGet full accessSanofi AB
ABActiveOrg 5564412574Franzéngatan 6 9trWholesale of pharmaceutical and medical goods · NACE 4646Est. 1992131 employees
Revenue 2024
SEK 1,5B
+15% vs 2023
EBITDA margin
4.5%
+84% vs 2023
Equity ratio
10.2%
Financial strength
Net profit 2024
SEK 49,9M
+91% vs 2023
| Revenue | SEK 1,5B | +15% |
| EBITDA | SEK 69,4M | +84% |
| Net profit | SEK 49,9M | +91% |
| Total assets | SEK 833,1M | +7% |
| Equity | SEK 84,8M | +39% |
| Employees | 131 | — |
Legal name
Sanofi AB
Org number
5564412574
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
11 februari 1992
Share capital
SEK 2 630 000
Employees
131 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Sandgren, Daniel Andreas Firman tecknas av Zheng, Hao i förening med Fredlund Olsson, Jan Christer
Company purpose
Föremålet för bolagets verksamhet är att utveckla, registrera, tillverka eller låta tillverka, marknadsföra och sälja farmaceutiska produkter och basläkemedel och att forska kring, utveckla, producera, marknadsföra och försälja biologiska preparat inom hälso- och sjudvårdsområdet, samt därmed förenlig verksamhet.
Address
Franzéngatan 6 9tr
Phone
+4686345000
Email
infoavd@sanofi-aventis.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 1997 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 872 981 | 846 247 | 959 025 | 1 019 450 | 1 142 652 | 1 128 844 | 1 338 172 | 1 539 846 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 0 | 22 373 | 26 318 | 26 332 | 32 677 | 59 719 | 148 840 | 60 114 | 56 065 | 37 704 | 69 431 |
| Depreciation & amort. | — | — | — | — | — | — | — | — | — | — | — |
| EBIT | 0 | 22 373 | 26 318 | 26 332 | 32 677 | 59 719 | 148 840 | 60 114 | 56 065 | 37 704 | 69 431 |
| Net financials | — | −204 | −236 | −569 | −844 | −488 | −1 396 | −125 | −1 178 | 345 | 461 |
| Profit before tax | 0 | 33 375 | 45 353 | 37 191 | 33 960 | 59 834 | 130 838 | 52 143 | 51 806 | 38 049 | 69 975 |
| Tax | — | −8 249 | −10 754 | −9 209 | −8 395 | −14 011 | −29 037 | −11 822 | −11 792 | −12 000 | −20 117 |
| Net profit | — | 25 126 | 34 599 | 27 982 | 25 565 | 45 823 | 101 801 | 40 321 | 40 014 | 26 049 | 49 858 |
| Item | 1997 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | 488 090 | 419 249 | 445 571 | 450 015 | 573 221 | 630 840 | 595 804 | 556 503 | 777 026 | 833 148 |
| Equity | — | 106 115 | 112 576 | 105 959 | 131 524 | 123 800 | 190 044 | 127 216 | 74 962 | 60 997 | 84 806 |
| Long-term debt | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | — | 286 007 | 229 977 | 274 343 | 255 022 | 386 555 | 361 259 | 381 173 | 391 044 | 625 532 | 657 845 |
| Total debt | — | 286 007 | 229 977 | 274 343 | 255 022 | 386 555 | 361 259 | 381 173 | 391 044 | 625 532 | 657 845 |
EBITDA margin
4.5%
This company
15.8%
Market median
-72% vs market
19972024
Equity ratio
10.2%
This company
38.2%
Market median
-73% vs market
19972024
Return on equity
58.8%
This company
18.4%
Market median
+220% vs market
19972024
Net profit margin
3.2%
This company
8.1%
Market median
-60% vs market
19972024
Asset turnover
1.85×
This company
1.12×
Market median
+65% vs market
19972024
Debt / equity
8.82×
This company
0.62×
Market median
-1323% vs market
19972024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
- Annual report 1997Filed via Bolagsverket / SCB · Period 1997-01-01 – 1997-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BS Chief Auditor | Chief Auditor | 2020 | — | — |
EÅ Chief Auditor | Chief Auditor | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Deputy Board Member | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
SANOFI-AVENTIS PARTICIPATION SA | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SANOFI-AVENTIS PARTICIPATION SA
Sanofi AB (this company)Board members of Sanofi AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Börje Stefan Andersson Berglund | Chief Auditor | 0 companies |
| Erik Åke Martin Kraft | Chief Auditor | 0 companies |
| Per Rickard Öhlén | Chairman | 0 companies |
| Anna-Kaija Grönblad | Chairman | 0 companies |
| Thomas Ivar Wallman | Deputy Board Member | 0 companies |
| Pieter Wester Oldenziel | Board of Directors | 0 companies |
| Daniel Andreas Sandgren | Chairman | 0 companies |
| Hao Zheng | Board of Directors | 0 companies |
| Jan Christer Fredlund Olsson | Deputy Board Member | 0 companies |